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 INTRODUCTION
Gastroenteropancreatic neuroendocrine tumours are rare 
with an annual incidence rate of less than 10 per million pop-
ulation [1]. Th ese tumours can be subdivided into non-func-
tioning and functioning, the latter referring to tumours capa-
ble of secreting peptide hormones or biogenic amines into 
the circulation in a dysregulated manner to produce deﬁ ned 
tumour syndromes with varying clinical manifestations.
Glucagonomas arise mostly from pathological trans-
formation of pancreatic islet α-cells that synthesise and 
secrete proglucagon-derived peptides (Figure  1). Th ese rare 
tumours have an annual incidence of 1 per 20-40 million 
population  [2]; however autopsy studies have reported the 
incidence of islet cell tumours with glucagon expressing cells 
to approximate 1 suggesting that a number of tumours are 
undiagnosed and/or associated with sub-clinical disease [3]. 
Th e vast majority of proglucagon-expressing tumours are 
sporadic (80) with the remainder associated with Multiple 
Endocrine Neoplasia-type  1 (MEN1), an inherited tumour 
predisposition syndrome, or Mahvash disease, an extremely 
rare cause of familial pancreatic α-cell hyperplasia and 
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Abstract
Pancreatic islet α-cell tumours that overexpress proglucagon are typically associated with the glucagonoma syndrome, a rare disease entity 
characterised by necrolytic migratory erythema, impaired glucose tolerance, thromboembolic complications and psychiatric disturbances. 
Paraneoplastic phenomena associated with enteric overexpression of proglucagon-derived peptides are less well recognized and include 
gastrointestinal dysfunction and hyperinsulinaemic hypoglycaemia. Th e diverse clinical manifestations associated with glucagon-expressing 
tumours can be explained, in part, by the repertoire of tumorally secreted peptides liberated through diﬀ erential post-translational processing 
of tumour-derived proglucagon. Proglucagon-expressing tumours may be divided into two broad biochemical subtypes deﬁ ned by either secre-
tion of glucagon or GLP-1, GLP-2 and the glucagon-containing peptides, glicentin and oxyntomodulin, due to an islet α-cell or enteroendocrine 
L-cell pattern of proglucagon processing, respectively. In the current review we provide an updated overview of the clinical presentation of pro-
glucagon-expressing tumours in relation to known physiological actions of proglucagon-derived peptides and suggest that detailed biochemical 
characterisation of the peptide repertoire secreted from these tumours may provide new opportunities for diagnosis and clinical management.
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Box 1. Learnings Points
• Proglucagon-derived peptides exhibit a diverse range of 
biological activities including critical roles in regulation of 
glucose and amino acid metabolism, and possibly also aﬀ ect 
energy homeostasis as well as cardiovascular and gastrointes-
tinal function.
• Clinical manifestations of proglucagon-expressing tumours 
exhibit marked phenotypic variation possibly due to hetero-
geneity of their secreted peptide repertoire.
• Speciﬁ c and precise biochemical assessment of individuals 
with proglucagon-expressing tumours may provide opportu-
nities for improved diagnosis and clinical management.
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glucagonoma due to inactivating mutations in the glucagon 
receptor (GCGR) gene [4].
CLINICAL HETEROGENEITY OF 
GLUCAGONOMAS
Only a subset of glucagonomas manifest clinical symptoms 
resulting in a spectrum of disease; ranging from an asymp-
tomatic patient to one with hallmarks of the glucagonoma 
syndrome. Th e classic features associated with glucagonomas 
include a characteristic dermatitis termed necrolytic migratory 
erythema (NME), weight loss, impaired glucose tolerance or 
diabetes mellitus, painful glossitis, stomatitis, diarrhoea, throm-
boembolic complications and psychiatric disease [5]. More 
recently, scattered reports have also described glucagonomas 
presenting with acute heart failure and dilated cardiomyopathy 
that are reversible following therapeutic normalization of circu-
lating glucagon levels [6, 7]. Less commonly recognized are the 
paraneoplastic phenomena associated with tumoral secretion 
of proglucagon-derived GLP-1 and GLP-2 which may present 
with hyperinsulinaemic hypoglycaemia and marked gastroin-
testinal dysfunction (refractory constipation, reduced motility, 
gross structural abnormalities of the small intestine), respec-
tively [8-10] (Figure 2). Th e diagnosis of glucagonoma is estab-
lished by demonstrating hyperglucagonaemia (>500  mg/mL). 
However, in the absence of clinical symptoms and signs the 
diagnosis should be reconsidered given elevated glucagon levels 
are also found in association with cirrhosis, renal failure, pancre-
atitis, diabetes mellitus, prolonged fasting and familial hyperglu-
cagonaemia [2,11] (thus not as high as the glucagonomas).
NME is a presenting feature in 70 of patients with glu-
cagonoma. It is usually widely distributed with the groin, 
perineum and distal extremities most commonly aﬀ ected. 
Clinically, NME is characterized by raised erythematous lesions 
with fragile bullae that break down and shed into crusted areas 
of hyperpigmentation. Histological examination of biopsied 
skin demonstrates small bullae and necrolysis of the upper epi-
dermis. Although the aetiology of NME remains unclear, histo-
logical similarities with pellagra (nicotinic acid deﬁ ciency) and 
acrodermatitis enteropathica (zinc deﬁ ciency) suggest NME 
is a consequence of nutrient deﬁ ciency. A  number of case 
reports have also described iatrogenic NME following intrave-
nous glucagon infusion suggesting that PGDPs may have direct 
eﬀ ects on the skin [12]. Interestingly, despite profound hyper-
glucagonaemia, patients with Mahvash disease do not develop 
NME thereby suggesting that intact glucagon-receptor signal-
ling is required for NME pathogenesis [4,13]. NME invariably 
improves with normalization of glucagon levels through either 
surgical reduction of tumour burden or medical treatment 
with somatostatin analogues [14].
FIGURE 1. Tissue speciﬁ c processing of proglucagon. In the pancreatic α-cell, proglucagon is processed by PC2 activity into GRPP, glu-
cagon, major proglucagon fragment (MPGF). In the L-cells, proglucagon is processed by PC1/3 into GLP-1 (7-36NH2) GLP-2 and glicentin. 
By further PC1/3 activity, glicentin can then be further cleaved into glicentin related pancreatic polypeptide (GRPP) and oxyntomodulin. 
N-terminal elongated glucagon has also been reported and is termed intestinal glucagon or enteroglucagon. Black arrowheads refer 
to side-viewing proglucagon antibodies, red arrowheads refer to N-terminal glucagon/oxyntomodulin antibodies and blue arrowheads 
refer to C-terminal glucagon antibodies. Glucagon measurement should therefore be carried out using, preferably a sandwich ELISA 
employing N and C-terminal glucagon antibodies. Assay only using black, blue or red antibodies (as depicted here) may over or under-
estimate glucagon levels due to cross-reactivity with other proglucagon molecules such as glicentin, oxyntomodulin or enterogluca-
gon 1-61.
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Weight loss is the most common presenting feature of 
proglucagon-expressing tumours reﬂ ecting important roles 
for proglucagon-derived peptides in the regulation of energy 
homeostasis [15,16]. GLP-1 and glucagon act independently 
to potently inhibit food intake through activation of central 
satiety centres. In addition, glucagon modulates energy bal-
ance through stimulation of energy expenditure possibly via 
the sympathetic nervous system to activate thermogenesis 
in brown adipose tissue (BAT). Whilst such an eﬀ ect of glu-
cagon has been repeatedly demonstrated in experimental 
animal models the importance of BAT activation in human 
energy balance remains uncertain. Nevertheless, GLP-1 and 
glucagon both promote negative energy balance which may 
result in profound weight loss in pathological states, such 
as in the glucagonoma syndrome, when these peptide hor-
mones may be secreted at high levels.
Glucagon is the archetypical counter-regulatory hormone, 
which is normally released in response to hypoglycaemia to 
promote hepatic glucose production but is also essential for 
maintenance of euglycaemia in the fasting state. Despite these 
actions, diabetes mellitus is not an inevitable consequence of 
the glucagonoma syndrome although the presence of diabe-
tes mellitus shown to correlate directly with plasma glucagon 
levels [17]. Glucagon strongly stimulates insulin secretion, 
which of course has opposite eﬀ ects on glycaemia, which may 
explain that not all patients with high glucagon levels have 
diabetes. In these cases, diabetes may develop secondary to 
impairment of pancreatic endocrine function because of the 
tumour. It is unclear, however, whether patients with mildly 
elevated glucagon levels have impaired glucose intolerance 
in the absence of the full blown glucagonoma syndrome. 
Moreover, it is not known whether patients with sub-clinical 
disease are at increased risk of thromboembolic, gastrointesti-
nal or cardiovascular complications is not known and further 
study is required to determine whether such patients would 
beneﬁ t from prophylactic anticoagulation and/or regular 
echocardiographic assessment of cardiac function.
Finally, similar with other pancreatic neuroendocrine 
tumours, glucagonomas may co-secrete a multitude of hor-
mones including insulin, PYY, pancreatic polypeptide, ACTH, 
PTH, somatostatin and PTHrP, thereby adding further com-
plexity to the clinical phenotype. Th ese endocrine distur-
bances which may delay correct diagnosis [18].
MOLECULAR HETEROGENEITY OF 
GLUCAGONOMAS
Th e variable clinical phenotypes seen with progluca-
gon-expressing tumours may be due, in part, to the speciﬁ c 
secreted peptide repertoire derived from proglucagon in that 
tumour. Th e physiology of proglucagon derived peptides have 
been comprehensively reviewed elsewhere [19-24]. Here, we 
provide a brief overview of the processing and physiological 
actions of proglucagon-derived peptide hormone as they 
relate to proglucagon-expressing tumours.
As illustrated in Figure  1, post-translational proglucagon 
processing diﬀ ers between pancreatic islet α-cells and intesti-
nal enteroendocrine L-cells. Th e biologically most important 
FIGURE 2. The molecular heterogeneity of glucagonomas results in diﬀ erential clinical phenotype. As illustrated patients suﬀ ering with 
glucagonomas shares common features (right panel) however and clinical important they may depending on the molecular processing 
of proglucagon also.
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product of α-cell proglucagon processing is presumably gluca-
gon, a 29 amino acid hormone which is formed from progluca-
gon together with the probably inactive processing products, 
glicentin-related pancreatic polypeptide (GRPP) (correspond-
ing to proglucagon 1-30) and Major Proglucagon Fragment 
(MPGF) (corresponding to proglucagon 72-158), as a result 
of the actions of prohormone convertase 2 (PC2) in these 
cells [25]. Intestinal proglucagon-expressing enteroendocrine 
L cells, distributed throughout the small and large intestine, do 
not, at least normally and in healthy subjects, secrete glucagon 
(33-61) but rather liberate glicentin, oxyntomodulin, GLP-1 
and GLP-2 derived from proglucagon following tissue-spe-
ciﬁ c processing by prohormone convertase 1/3 (PC1/3). Th e 
intact, bioactive GLP-1 moieties, GLP-1(7-36) amide (~90  in 
humans [26]) and GLP-1(7-37) (~10 , but more so e.g. in rats 
and pigs [27]), are released upon appropriate stimulation of 
the L cells and mediate their biological actions through activa-
tion of the GLP-1 receptor expressed in pancreatic β-cells and 
several extrapancreatic tissues including brain, heart, kidney 
and peripheral and enteric nervous systems.
Hyperglucagonemia may disrupt glucose homeostasis 
through opposing mechanisms as either a diabetogen to pro-
mote hyperglycemia and/or promoting post-prandial hypo-
glycemia through stimulation of insulin secretion [28]. In 
glucagonoma, the diabetogenic eﬀ ects of glucagon may pre-
dominate as up to 80 of patients have a diagnosis of diabetes 
mellitus at presentation [29,30]. Whilst pancreatic derived 
glucagon appears important in both health and disease, it is 
intriguing to note that hyperglucagonaemia is also found in 
patients who have undergone pancreatectomy, suggesting 
that the intestinal L-cell may be a potential source of circulat-
ing fully processed glucagon (sequence 33-61) in some disease 
states [31].
Th e observations that GLP-1, an incretin hormone, has 
glucose-lowering properties and attenuates glucagon secre-
tion have stimulated pharmaceutical development of several 
GLP-1 analogues, such as exenatide and liraglutide, for the 
treatment of type 2 diabetes. Notably, when used in isolation 
these therapies are associated with low risk of hypoglycaemia. 
Proglucagon expressing tumours that secrete GLP-1 have been 
described and appear to result in hypoglycaemia [8]. Roberts 
et al reported GLP-1  secretion from a metastatic pancreatic 
NET resulting in pancreatic β-cell hyperplasia and hyperinsu-
linism [32] whereas Todd and colleagues described an ovarian 
NET co-secreting GLP-1 and somatostatin presenting with 
both reactive hypoglycaemia and diabetes [33]. Interestingly, 
however, symptomatic hypoglycaemia is not a presenting 
feature of all GLP-1  secreting NETs (Brubaker et al, Byrne et 
al) which may be due to aberrant proglucagon processing by 
the tumour to produce biologically inactive but immunoreac-
tive GLP-1 moieties [9,34]. When tumorally secreted, GLP-1 
mediated hypoglycaemia is suspected, biochemical conﬁ rma-
tion of elevated fasting levels of bioactive GLP-1 during hypo-
glycaemia is required. Further evidence may provided by the 
absence of insulin expression in tumour biopsies and improve-
ment of hypoglycaemia following normalization of GLP-1 lev-
els and/or presence of pancreatic islet cell hyperplasia which 
has been observed when GLP-1 secreting tumours are present 
[32,35].
In humans, intestinal enteroendocrine L-cells synthesise 
glicentin which may be processed further by PC1/3 to liberate 
GRPP and oxyntomodulin, a peptide hormone with the ability to 
increase insulin and glucagon secretion ex-vivo and in-vivo [36,37] 
as well as inhibit appetite and promote weight loss in overweight 
subjects [38]. Glicentin has no known eﬀ ect on glucose or appetite 
regulation but early reports proposed that this peptide hormone 
may possess intestinotropic properties following descriptions of 
patients with giant duodenal villi and small bowel hypertrophy 
due to glicentin-secreting proglucagonomas [39-41]. Advances 
in immunoassays capable of measuring speciﬁ c proglucagon-de-
rived peptides in concert with improved understanding of the 
roles of PDGPs in gastrointestinal physiology suggest these early 
observations were not solely due to elevated glicentin and more 
likely reﬂ ect the intestinotropic actions of GLP-2. In response to 
gut injury, GLP-2 promotes nutrient absorption through activa-
tion of crypt cell proliferation and expansion of small bowel epi-
thelium and perhaps more importantly inhibits epithelial apopto-
sis. Th erapeutically, a synthetic GLP-2 analogue (teduglutide) is 
approved for treatment of short bowel syndrome and intestinal 
failure [42]. GLP-1 is also intestinotropic but appears less eﬃ  ca-
cious than GLP-2 and is a more potent inhibitor of gastric motility 
when compared with GLP-2 [21].
Initial recognition of an association between the devel-
opment of intestinal villous hyperplasia and proglucagon 
derived peptides was provided by clinical description of a 
patient with features of the glucagonoma syndrome and giant 
duodenal villi due to an enteroglucagon producing tumour 
of the kidney  [41]. Subsequent reports have conﬁ rmed these 
early ﬁ ndings and identiﬁ ed tumoral co-secretion of GLP-2 
and GLP-1 as the peptide hormones responsible for intestinal 
villous hyperplasia associated with refractory constipation, 
reduced absorptive capacity, delayed gastric emptying, nausea 
and vomiting [2,9,43,44]. We recently described the ﬁ rst case 
of hyperinsulinaemic hypoglycaemia and marked gastrointes-
tinal dysfunction due to a GLP-1 and GLP-2 secreting tumour 
(Challis et al unpublished observations). Here, the use of immu-
noassays directed against speciﬁ c PDGPs in combination with 
size-exclusion chromatography allowed for detailed biochem-
ical characterization of the secreted peptide repertoire [40,45].
PGDPs inﬂ uence cardiovascular biology through a diverse 
range of actions. Glucagon, for example, has well recognized 
chronotropic actions on the heart and therapeutically is 
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considered the drug of choice for treating bradycardia and 
hypotension due to beta-blocker poisoning. Whilst current 
understanding of glucagon action in the human heart is lim-
ited, recent data derived from murine models of reduced 
glucagon signalling in cardiomyocytes suggest that following 
myocardial infarction, glucagon negatively inﬂ uences survival, 
cardiac hypertrophy and left ventricular remodelling [46]. In 
contrast, several studies have demonstrated that GLP-1 has 
cardio-protective actions mediated via several independent 
and poorly understood mechanisms some of which involve 
may involve GLP-1R activation in atrial cardiomyocytes. 
However, pharmacological strategies that promote increased 
GLP-1 levels in subjects with type  2 diabetes mellitus have 
not consistently demonstrated improved cardiovascular 
outcomes in large randomized controlled trials [48,49]. In 
patients with glucagonoma, single cases of reversible acute left 
ventricular dysfunction [6] and dilated cardiomyopathy [7] in 
association with hyperglucagonaemia have been described, 
but overall cardiac decompensation is a rare consequence 
of pathological levels of glucagon. As questioned previously, 
whether patients with sub-clinical disease and mild elevations 
in glucagon are at risk of clinically signiﬁ cant cardiac dysfunc-
tion is not known and we would advocate echocardiographic 
surveillance for such patients.
Th e secretory output of glucagonomas depends on the 
tumoural expression of PC1/3 or PC2. Although likely rare, 
given the limited number of reported cases, there is some evi-
dence to suggest that glucagonomas may undergo a transition 
from a α-cell processing proﬁ le (PC2-medicated processing) 
to one that resembles the enteroendocrine L-cell (PC1/3-
mediated processing [32]. IL-6 [50] and metabolic stress, such 
as hyperglycaemia [51], have been shown to induce PC1/3 
expression in pancreatic α-cells and in the context of malig-
nancy circulating pro-inﬂ ammatory cytokines may alter the 
tumour phenotype. Clinically, this may present with GLP-1 
mediated hyperinsulinaemic hypoglycaemia in an individ-
ual with a previous history of diabetes or features of the glu-
cagonoma syndrome. Indeed, several such cases have been 
reported in the medical literature [32].
BIOCHEMICAL ASSESSMENT OF 
HYPERGLUCAGONAEMIA
Measurement of glucagon remains a key element in the 
diagnosis of glucagonomas. However, the diﬀ erentiation 
between tumoural hypersecretion of pancreatic glucagon and 
glucagon-like immunoreactivity (Figure 1 and 2) is challenging 
and may aﬀ ect the subsequent choice of treatment strategy 
[45]. How can this be challenging? Th ere may, at least, be two 
explanations both related to the biochemical assessment of 
pancreatic glucagon. First, immuno-based detection methods 
(be it radioimmunoassays or ELISAs) may lack speciﬁ city for 
pancreatic glucagon (33-61) as the L-cell derived peptides gli-
centin and oxyntomodulin contains the glucagon sequence 
(see Figure 1) and, in addition, that GLP-1 and GLP-2 shares 
amino acid similarities. Several glucagon kits claimed to be 
speciﬁ c have been demonstrated not to be with some even 
detecting other proglucagon derived peptides but not pancre-
atic glucagon [52]. Secondly, the pancreatic speciﬁ c glucagon 
kits employing C-terminal antibodies (this is the classic way 
of measuring glucagon [30]) may also react with N-terminal 
elongated forms [45] and thereby overestimating pancreas 
(33-61) speciﬁ c glucagon.
FUTURE OUTLOOK FOR IMPROVED 
DIAGNOSTIC AND TREATMENT OF 
GLUCAGONOMAS
In summary, tumoural expression of proglucagon-derived 
peptides may result in a diverse spectrum of clinical pheno-
types dependent on the speciﬁ c secreted peptide repertoire. 
Th e advent of biochemical methods that quantify speciﬁ c 
tumour-derived proglucagon-derived peptides has provided 
opportunities for detailed tumour phenotyping, biochemical 
sub-classiﬁ cation and improved understanding of the clinical 
manifestations associated with these rare tumours.
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